Lowest Price Guaranteed From USD 3,499
The respiratory disorders market is estimated to be worth $5 billion in 2018 and is expected to grow at compounded annual growth rate (CAGR) of 14.7% during the forecast period. According to the Forum of International Respiratory Societies, around 4 million individuals die each year due to chronic respiratory diseases. The World Health Organization (WHO) estimates the global prevalence of two of the most common chronic respiratory diseases, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. Specifically, COPD is currently known to be the fourth leading cause of death worldwide. According to the data provided by the WHO, more than 3 million people die annually from COPD; this represents a total of 6% of the global annual deaths. Around 90% of these deaths occur in low and middle-income countries. Asthma, on the other hand, is more common in pediatric population. Asthma alone results in more than 30% of pediatric hospitalizations. Moreover, it is responsible for around 180,000 annual deaths worldwide.
In addition to asthma and COPD, other chronic respiratory disorders are also associated with high unmet needs. Specifically, the patients suffering from cystic fibrosis, which is known to have a global prevalence of 70,000, have reported median lifespan of less than 30 years. In addition, the patients suffering from cystic fibrosis are at a relatively higher risk of acquiring life threatening lung infections. The high prevalence, high rate of hospitalization and high cost of treatment for these disorders places a huge burden on the society in terms of direct healthcare costs and the loss of productivity associated with disability and premature mortality of the patients.
Although these diseases cannot be cured, government agencies and big pharma companies have made significant investments in R&D to improve disease management and address the unmet needs. These investments and development initiatives have led to the approval of several therapies, such as LAMA / LABA fixed dose combinations, ICS / LAMA / LABA fixed combinations, CFTR modulators, and novel biologics and antibiotics, which have helped improve the quality of life of patients. The industry is gradually transitioning towards the development of more targeted therapies. This shift is facilitating a scenario, wherein therapeutic strategies are changing from broad spectrum remedies to those that target individual patient segments.
Examples of key companies engaged in respiratory disorders market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, GlaxoSmithKline, Novartis, Teva Pharmaceutical, Vertex Pharmaceuticals, CURx Pharmaceuticals, Laurent Pharmaceuticals, Sanofi, Gilead Sciences and AB Science. This market report includes an easily searchable excel database of all the companies providing novel drugs and smart devices for respiratory disorders, worldwide.
The ‘Respiratory Disorders Market, 2018-2030’ market report provides a comprehensive study on the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the respiratory disorders market. The field has captured the interest of several drug developers, both small and large companies. With several novel drug candidates in development, we anticipate the respiratory disorders market to witness continued market growth during the forecast period. Amongst other elements, the market research report features:
The key objective of respiratory disorders market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for respiratory disorders market during the forecast period. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the forecast period 2018-2030. The research, analysis and insights presented in this market research report include potential sales of novel therapies, as well as smart inhalers that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the market report were influenced by discussions with senior stakeholders in the respiratory disorders market. These include Antonio Anzueto (Pulmonologist, University of Texas Health Science Center), Richard Moss (Pediatric Pulmonologist, Lucile Packard Children’s Hospital, Stanford University), Alex Stenzler (Founder and President, Novoteris), Dinesh Srinivasan (Director, Anthera Pharmaceuticals) and Dinu Sen (CEO, CURx Pharmaceuticals). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.